SEEDSUPPLY has developed Binder Selection Technology (BST,) a unique method that can screen compounds bound to any type of target with a single high-throughput method. The targets BST can screen are not limited to soluble protein. It can be used with targets including orphan receptors, ion channels, transporters, membrane proteins, and scaffold proteins with no biological activity. We can also obtain POI ligands of PROTACs as silent binders.
BST’s efficiency opens doors to a new paradigm of drug discovery. Traditionally, drug discovery sequentially goes through target idea generation, assay development for each target, target verification, and finally hit generation. Developing assays for different targets is time consuming, yet not all validated targets generate hits. Instead, BST lets us take an agile approach. We can quickly test if a target has any hits before taking time to validate the target. We can go through many iterations of target ideas and hit generation instead of making big bets that can turn out to be wrong years later.
We are using BST to build a binder collection against targets. So far, we have hits for 197 GPCRs including orphan GPCRs and 154 SLC transporters.
BST can also be used for target deconvolution with our protein library of 18,000 proteins. Our screening can be performed without having to chemically modify the compound or immobilize the protein.
Let us introduce how BST can accelerate your drug discovery.
.jpg "Naoki Tarui photo")